At ADA 2026, Eli Lilly and Novo Nordisk unveiled competing oral semaglutide-class drugs, with Lilly widening its obesity drug lead amid growing competition from AZ, Pfizer, and Boehringer.

Lilly's dual GIP/GLP-1 agonist data reinforced analyst view that the company is widening its lead in competitive obesity market despite field crowding.

GSK closed major acquisition of Nuvalent, gaining two late-stage cancer programs to compete with Roche, Pfizer in lung cancer market.

Two Phase 3 trials met efficacy goals for Merck and Gilead's combined regimen, positioning it as first long-acting oral HIV treatment taken weekly.

AZ revealed oral GLP-1 data at ADA showing competitive weight loss versus rivals, advancing toward Phase 3 with potential to capture oral market segment.

Zealand's obesity drug candidate faced investor skepticism after trial data revealed tolerability issues and patient dropouts, sharply contrasting with competitor efficacy readouts.

Pfizer posted Phase IIb data for its monthly GLP-1 RA injection in obesity, positioning itself as a potential challenger to weekly injectables from Novo and Lilly.

At ADA, Boehringer and Zealand presented Phase 3 data showing weight loss and fat reduction but acknowledged tolerability challenges; company insists profile is 'consistent with class.'

J&J paid $1B upfront for Firefly's degrader antibody conjugate platform, entering emerging DAC modality to expand oncology options.

WA's controversial pricing legislation survived judicial review, setting precedent for state-level drug cost controls.

Novo Nordisk's recently launched GLP-1 pill garnered 3 million prescriptions, suggesting strong patient demand for oral obesity option.

Incyte's CEO Bill Meury led company's biggest deal to acquire Star subsidiary with bleeding disorder candidate in late development.

Leading CDMO included on U.S. government list as biotechnology company of concern under Biosecure Act scrutiny.

Novo Nordisk gained FDA approval for higher-dose version of its GLP-1 pill, offering dose escalation for patients seeking greater weight loss.

Regulatory agency initiated safety review of widely used abortion medication amid political pressure, potentially enabling restrictive action.

Cellectis secured Regenerative Medicine Advanced Therapy designation for its allogeneic CAR-T candidate, potentially accelerating development path.

Eli Lilly secured a gamma-secretase modulator for Alzheimer's in heavily backloaded deal, expanding pipeline beyond metabolic diseases.

Pfizer's factor VIII replacement therapy gained expanded label to include all pediatric patients 6+, broadening commercial opportunity in hemophilia.

Inhaled insulin Afrezza gained pediatric indication, expanding addressable population and commercial prospects for rapid-acting formulation.

Nuvalent shares surged on combined speculation regarding potential acquisition by GSK and regulatory success for lung cancer programs.

Antibody-drug conjugate therapy faced investor scrutiny after imbalanced mortality signal in clinical trial, raising long-term viability concerns.

Essential chemotherapy agents face supply constraints, raising concerns about cancer treatment continuity and patient care disruption.

Industry momentum sustained despite headwinds, with expanded deal activity, IPO launches, and VC funding supporting continued consolidation.

Transcranial magnetic stimulation therapy maintained long-term depression relief in majority of patients, supporting durable efficacy claim.